Codexis, a leading developer of biocatalysts for chemistry-based manufacturing applications in the pharmaceutical and biofuel industries, withdrew its IPO on Wednesday in a filing citing unfavorable market conditions. The company planned to list its shares on the NASDAQ under the ticker CDXS, but deal terms had not been announced. Credit Suisse and Goldman Sachs were set to be the lead underwriters on the deal.
